# US 2026/0100251 A1 · Methods for Rule-based Genome Design

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0100251 A1
- Document ID: US20260100251A1
- Status: Published application
- Kind: A1
- Application number: 18/901,470
- Filed: 2024-09-30
- Published: 2026-04-09
- Earliest claimed: 2016-06-15
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: Gleb Kuznetsov; Marc J. Lajoie; Matthieu M. Landon; Michael G. Napolitano; Daniel Bryan Goodman; Christopher J. Gregg; George M. Church; Nili Ostrov
- Web page: https://patentgrep.com/patent/US20260100251A1

## CPC

- G16B 35/10: Design of libraries
- C07K 14/245: Escherichia (G)
- C12N 15/1089: {Design, preparation, screening or analysis of libraries using computer algorithms}
- C12N 15/67: General methods for enhancing the expression
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- G16B 20/50: Mutagenesis
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods and systems for designing, testing, and validating genome designs based on rules or constraints or conditions or parameters or features and scoring are described herein. A computer-implemented method includes receiving data for a known genome and a list of alleles, identifying and removing occurrences of each allele in the known genome, determining a plurality of allele choices with which to replace occurrences in the known genome, generating a plurality of alternative gene sequences for a genome design based on the known genome, wherein each alternative gene sequence comprises a different allele choice, applying a plurality of rules or constraints or conditions or parameters or features to each alternative gene sequence by assigning a score for each rule or constraint or condition or parameter or feature in each alternative gene sequence, resulting in scores for the applied plurality of rules or constraints or conditions or parameters or features, scoring each alternative gene sequence based on a weighted combination of the scores for the plurality of rules or constraints or conditions or parameters or features, and selecting at least one alternative gene sequence as the genome design based on the scoring.

## Claims

### Claim at position 1

-26. (canceled)

### Claim 27

An engineered organism comprising a recoded genome, wherein the organism is E. coli, wherein the recoded genome comprises at least one trinucleotide sequence corresponding to a particular codon at all or substantially all instances in a corresponding template genome that is replaced with a trinucleotide sequence corresponding to an alternative codon, wherein the particular codon is UAG, and wherein the prfB gene comprises a mutation relative to the corresponding template genome.

### Claim 28 (depends on 27)

The engineered organism of claim 27, wherein the mutation is in a trinucleotide sequence corresponding to a forbidden sense codon.

### Claim 29 (depends on 28)

The engineered organism of claim 28, wherein the forbidden sense codon is selected from the group consisting of: AGA, AGG, AGC, AGU, UUA, and UUG.

### Claim 30 (depends on 29)

The engineered organism of claim 29, wherein the forbidden codon is AGG or AGC.

### Claim 31 (depends on 27)

The engineered organism of claim 27, wherein the mutation comprises a frameshift mutation.

### Claim 32 (depends on 27)

The engineered organism of claim 27, wherein the mutation is in the following prfB gene template sequence: 5′-CTTAGGGGGTATCTTTGAC-3′.

### Claim 33 (depends on 32)

The engineered organism of claim 32, wherein the mutation comprises a mutation in the trinucleotide sequence corresponding to at least one of XXX1, XXX2, and XXX3 in the following prfB gene template sequence: 5′-XXXXXX2GGGTATCTTXXX3C-3′.

### Claim 34 (depends on 33)

The engineered organism of claim 33, wherein the mutation comprises a wobble mutation in the trinucleotide sequence corresponding to XXX1.

### Claim 35 (depends on 33)

The engineered organism of claim 33, wherein the mutation comprises a frameshift mutation in the trinucleotide sequence corresponding to XXX3.

### Claim 36 (depends on 27)

The engineered organism of claim 27, wherein the mutation comprises removing the nucleotide corresponding to X in the following prfB gene template sequence: 5′-CTTAGGGGGTATCTTXGAC-3′.

### Claim 37 (depends on 27)

The engineered organism of claim 27, wherein the nucleotide corresponding to X in the following prfB gene template sequence is mutated in the prfB gene: 5′-CTXAGGGGGTATCTTTGAC-3′.

### Claim 38 (depends on 27)

The engineered organism of claim 27, wherein the nucleotide corresponding to X2 in the following prfB gene template sequence is an adenine: 5′-CTTAGGGGGTATCTTX1X2-3′.

### Claim 39 (depends on 27)

The engineered organism of claim 27, wherein the mutation in prfB results in a mutated codon that is not reassigned to the non-standard amino acid.

### Claim 40 (depends on 27)

The engineered organism of claim 27, wherein the mutation in prfB comprises a first mutation in a trinucleotide sequence corresponding to a forbidden sense codon and a second mutation, wherein the second mutation results in a mutated codon that is not reassigned to the non-standard amino acid.

### Claim 41 (depends on 40)

The engineered organism of claim 40, wherein the forbidden sense codon is AGG or AGC.

### Claim 42 (depends on 40)

The engineered organism of claim 40, wherein the second mutation is in the following prfB gene template sequence: 5′-CTTAGGGGGTATCTTTGAC-3′.

### Claim 43 (depends on 42)

The engineered organism of claim 42, wherein the second mutation comprises a mutation in the trinucleotide sequence corresponding to XXX1 or XXX2 in the following prfB gene template sequence: 5′-XXX1AGGGGGTATCTTXXX2C-3′.

### Claim 44 (depends on 27)

The engineered organism of claim 27, wherein the mutation comprises a mutation in a trinucleotide sequence corresponding to a forbidden sense codon, and wherein the nucleotide corresponding to X2 in the following prfB gene template sequence is an adenine: 5′-CTTAGGGGGTATCTTX1X2-3′.

### Claim 45 (depends on 44)

The engineered organism of claim 44, wherein the forbidden sense codon is AGG or AGC.

### Claim 46 (depends on 27)

The engineered organism of claim 27, wherein the at least one trinucleotide sequence corresponding to the particular codon is reassigned to a non-standard amino acid.

### Claim 47 (depends on 27)

The engineered organism of claim 27, wherein ribosome binding site (RBS) strength is modulated by the mutation.

### Claim 48 (depends on 27)

The engineered organism of claim 27, wherein a gene encoding release factor 1 (RF1) is removed from the recoded genome.

### Claim 49 (depends on 27)

The engineered organism of claim 27, wherein the expression or function of release factor 1 (RF1) is impaired.

### Claim 50 (depends on 27)

The engineered organism of claim 27, further comprising an orthogonal aminoacyl-tRNA synthetase and/or tRNA.

### Claim 51 (depends on 27)

The engineered organism of claim 27, wherein the engineered organism is viable.

### Claim 52 (depends on 27)

A method comprising culturing the engineered organism of claim 27 in growth media that comprises at least one non-standard amino acid.

### Claim 53 (depends on 27)

A polypeptide comprising a non-standard amino acid, wherein the polypeptide is made using the engineered organism of claim 27.
